Clinical utility of novel biomarkers for prediction of early pregnancy failure
新型生物标志物预测早期妊娠失败的临床应用
基本信息
- 批准号:10563608
- 负责人:
- 金额:$ 71.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2028-01-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAreaBiologicalBiological MarkersCaringCause of DeathCessation of lifeCharacteristicsClinicalClinical ManagementClinical TrialsComplementConsumptionDataDevelopment PlansDiagnosisDiagnosticDiscipline of obstetricsDiscriminationDiseaseEctopic PregnancyEthnic OriginFirst Pregnancy TrimesterFundingGestational AgeGoalsGynecologicHemorrhageHuman Chorionic GonadotropinIatrogenesisInterruptionLocationMachine LearningMammalian OviductsMedicalMedical Care TeamMethodologyModelingMorbidity - disease rateNational Institute of Child Health and Human DevelopmentPainPathway interactionsPatientsPerformancePhysiologyPopulationPredictive ValuePredictive Value of TestsPregnancyPregnancy OutcomeProceduresProcessProductivityProspective StudiesProspective cohortProteomicsRaceRecording of previous eventsResearchResearch PriorityResourcesRiskRuptureSamplingSerumSigns and SymptomsSpontaneous abortionStressSubgroupSymptomsSystemTestingTimeUncertaintyUnited States National Institutes of HealthUterusValidationWomanWorkbiomarker developmentbiomarker panelbiomarker performanceclassification algorithmclinical carecompanion diagnosticsdesigndiagnostic toolearly pregnancyearly pregnancy lossfeature selectionhealth care deliveryimprovedinterestmachine learning algorithmmodel buildingnovelnovel markerpain symptompopulation basedpredictive markerpregnancy failurerandom forestregression treesscreeningultrasound
项目摘要
Abstract: The diagnosis and management for women who are at risk for ectopic pregnancy (EP) and
spontaneous abortion (SAB), has not changed substantially in decades. While ultrasound can diagnose a
significant portion of women at presentation, because of its limited accuracy in abnormal and early gestation, a
large number of women need serial tests and procedures to determine the final location and viability of an early
pregnancy. Misdiagnosis and iatrogenic complications during this time are still too common. This conundrum
results in great stress and uncertainty for women undergoing clinical care and their health care teams. To date,
we have demonstrated (and validated) that multiplexed biomarkers from divergent biological pathways can be
used to minimize both false positive and false negative discrimination (rather than balancing the two errors with
lower accuracy). In parallel, we have discovered and screened more than 54 novel biomarkers to obtain 11
candidates that can predict early pregnancy outcome. Using machine learning we have demonstrated that as
few as 3 of these markers can predict the location of an early gestation (IUP vs EP or SAB) with 95%
accuracy. Additionally, an overlapping group of 3 markers can predict the viability of a gestation (IUP vs SAB
or EP) with 94% accuracy. When both tests are used in combination the accuracy is 96.9%. We now plan to
externally validate these companion diagnostic(s) in a separate population-based prospective study and to
determine the optimal conditions of use. We will optimize performance in women presenting with a pregnancy
of unknown location as well as assess predictive values for all women presenting at risk for early pregnancy
loss using an independent population-based prospective study (SA1). We will determine if accuracy can be
improved with the combination of presenting signs, symptoms, and ultrasound findings (SA2). Moreover, we
will validate our biomarker tests in two distinct populations of interest: women with high and low risk for EP: a)
asymptomatic women prior to presentation for care (EAGeR Trial) and b) women diagnosed with a persistent
pregnancy of unknown location (ACTorNOT Trial) (SA3). Developing novel biomarkers that distinguish normal
physiology from the presence of gynecologic disorders is an NICHD research priority area. Our productive and
established team is proposing rigorous cross disciplinary, state of the art, and novel research with great
scientific impact that has the potential to produce a paradigm shift in clinical care models for the diagnosis and
management of women in early pregnancy. Our detailed plan for biomarker development is iterative and
nimble and, importantly, includes validation. Our development plan is informed by methodology from
successful biomarker development, is designed to minimize known pitfalls, and is developed with FDA
guidance.
翻译后摘要:诊断和管理的妇女谁是在危险的异位妊娠(EP)和
自然流产(SAB),几十年来没有发生实质性变化。虽然超声波可以诊断
由于其对异常妊娠和早期妊娠的准确性有限,
大量的妇女需要一系列的测试和程序,以确定最终的位置和可行性的早期
怀孕误诊和医源性并发症在这段时间仍然太常见。这个难题
这给接受临床护理的妇女及其卫生保健团队带来了巨大的压力和不确定性。到目前为止,
我们已经证明(并验证),来自不同生物途径的多重生物标志物可以
用于最小化假阳性和假阴性鉴别(而不是用
精度低)。与此同时,我们发现并筛选了超过54种新的生物标志物,
可以预测早期妊娠结果的候选人。使用机器学习,我们已经证明,
这些标记物中的几个可以预测早期妊娠的位置(IUP vs EP或SAB),95%
精度此外,一组重叠的3个标记物可以预测妊娠的生存能力(IUP vs SAB
或EP),准确率为94%。当两种测试结合使用时,准确度为96.9%。我们现在计划
在单独的基于人群的前瞻性研究中对这些伴随诊断进行外部验证,
确定最佳使用条件。我们将优化妊娠妇女的性能
以及评估所有存在早孕风险的女性的预测值
使用独立的基于人群的前瞻性研究(SA1)。我们将确定准确性是否可以
结合体征、症状和超声检查结果改善(SA2)。而且我们
将在两个不同的感兴趣的人群中验证我们的生物标志物测试:EP高风险和低风险的女性:a)
b)在就诊前无症状的女性(EAGeR试验)和B)诊断为持续性
未知部位妊娠(ACTorNOT试验)(SA3)。开发新的生物标志物来区分正常的
从妇科疾病的存在生理是NICHD的研究优先领域。我们的生产力和
一个成熟的团队正在提出严格的跨学科,最先进的,新颖的研究,
科学的影响,有可能产生一个范式转变的临床护理模式的诊断和
妇女在怀孕早期的管理。我们的生物标志物开发详细计划是迭代的,
灵活,重要的是,包括验证。我们的发展计划是根据以下方法制定的:
成功的生物标志物开发,旨在最大限度地减少已知的陷阱,并与FDA一起开发
指导
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kurt T Barnhart其他文献
Kurt T Barnhart的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kurt T Barnhart', 18)}}的其他基金
Early Double Low-Dose Aspirin to Reduce Preeclampsia and Miscarriage: a Global Approach RCT
早期双倍低剂量阿司匹林减少先兆子痫和流产:全球方法随机对照试验
- 批准号:
10711793 - 财政年份:2023
- 资助金额:
$ 71.84万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
8933128 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
9268010 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
8846129 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
8631014 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
CCTN - CONTRACEPTIVE CLINICAL TRIALS NETWORK - FEMALE SITES
CCTN - 避孕临床试验网络 - 女性站点
- 批准号:
10329724 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
Development of a serum biosignature for ectopic pregnancy.
异位妊娠血清生物特征的开发。
- 批准号:
9473793 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
相似国自然基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
- 批准号:2021JJ40433
- 批准年份:2021
- 资助金额:0.0 万元
- 项目类别:省市级项目
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
- 批准号:32001603
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
AREA国际经济模型的移植.改进和应用
- 批准号:18870435
- 批准年份:1988
- 资助金额:2.0 万元
- 项目类别:面上项目
相似海外基金
Tribal Intertidal Digital Ecological Surveys Project: Using Large-Area Imaging to Assess Intertidal Biological Response to Changing Oceanographic Conditions in Partnership with Indigenous Nations
部落潮间带数字生态调查项目:与土著民族合作,利用大面积成像评估潮间带生物对不断变化的海洋条件的反应
- 批准号:
532685-2019 - 财政年份:2022
- 资助金额:
$ 71.84万 - 项目类别:
Postgraduate Scholarships - Doctoral
Tribal Intertidal Digital Ecological Surveys Project: Using Large-Area Imaging to Assess Intertidal Biological Response to Changing Oceanographic Conditions in Partnership with Indigenous Nations
部落潮间带数字生态调查项目:与土著民族合作,利用大面积成像评估潮间带生物对不断变化的海洋条件的反应
- 批准号:
532685-2019 - 财政年份:2020
- 资助金额:
$ 71.84万 - 项目类别:
Postgraduate Scholarships - Doctoral
biological interactions among forest-dwelling fungus gnats and their natural enemies in shiitake mashroom production area
香菇产区森林真菌蚊与其天敌之间的生物相互作用
- 批准号:
19K06152 - 财政年份:2019
- 资助金额:
$ 71.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Tribal Intertidal Digital Ecological Surveys Project: Using Large-Area Imaging to Assess Intertidal Biological Response to Changing Oceanographic Conditions in Partnership with Indigenous Nations
部落潮间带数字生态调查项目:与土著民族合作,利用大面积成像评估潮间带生物对不断变化的海洋条件的反应
- 批准号:
532685-2019 - 财政年份:2019
- 资助金额:
$ 71.84万 - 项目类别:
Postgraduate Scholarships - Doctoral
To what extent does governance play a role in how effectively a marine protected area in the Irish Sea reaches its biological and socioeconomic goals?
治理在多大程度上对爱尔兰海海洋保护区如何有效实现其生物和社会经济目标发挥作用?
- 批准号:
2287487 - 财政年份:2019
- 资助金额:
$ 71.84万 - 项目类别:
Studentship
War and Biological Ageing in Vietnam: A Planning Grant to Foster Collaboration on a Novel Area of Global Research in Health and Ageing
越南的战争与生物衰老:一项规划拨款,以促进全球健康与老龄化研究新领域的合作
- 批准号:
404425 - 财政年份:2019
- 资助金额:
$ 71.84万 - 项目类别:
Miscellaneous Programs
Impact assessment of Noctiluca scintillans red tide on nutrient dynamics, biological processes in lower trophic levels and material cycle in the neritic area of Sagami Bay
夜光藻赤潮对相模湾浅海区营养动态、低营养层生物过程和物质循环的影响评估
- 批准号:
18K05794 - 财政年份:2018
- 资助金额:
$ 71.84万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Large-area graphene based chemical and biological sensors
基于大面积石墨烯的化学和生物传感器
- 批准号:
355863-2011 - 财政年份:2015
- 资助金额:
$ 71.84万 - 项目类别:
Discovery Grants Program - Individual
Large-area graphene based chemical and biological sensors
基于大面积石墨烯的化学和生物传感器
- 批准号:
355863-2011 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
Discovery Grants Program - Individual
Theoretical simulation and experimental study on biological weathering mechanism of the rock around coastal area in Yaeyama Islands
八重山群岛沿岸岩石生物风化机制的理论模拟与实验研究
- 批准号:
26790079 - 财政年份:2014
- 资助金额:
$ 71.84万 - 项目类别:
Grant-in-Aid for Young Scientists (B)